GlassScriptPhysician profile
Muhammad Asad Ali
NPI 1891750543
$7,089.69
in general payments reported to CMS, 2019-2025
40 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $601 · 2021: $1,261 · 2022: $1,342 · 2023: $967 · 2024: $1,175 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.33 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $888.70 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $749.28 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $685.96 | 2019-2024 | Xarelto, Opsumit |
| Astrazeneca Pharmaceuticals LP | $597.59 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Novo Nordisk INC | $427.76 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.24 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $359.41 | 2021-2025 | |
| Amarin Pharma, INC. | $345.43 | 2020-2023 | |
| Lilly USA, LLC | $318.30 | 2020-2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $310.14 | 2023-2024 | Inpefa |
| Pfizer INC. | $284.46 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $234.79 | 2021-2024 | Verquvo |
| Edwards Lifesciences Corporation | $141.99 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.82 | 2025 | Caplyta |
| Preventric Diagnostics, INC. | $128.91 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.